Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced on July 10, 2026, that its Compensation Committee granted inducement awards to eight new employees on July 6, 2026, under its 2024 Inducement Plan. The awards comprise non-qualified stock options to purchase 32,100 shares and RSUs underlying 16,050 shares of Class A common stock, with stock options carrying an exercise price of $40.13 per share. Both award types vest over four years, with stock options vesting 25% on the first anniversary and monthly thereafter over 36 months, while RSUs vest 25% annually on each anniversary of August 20. The grants were approved in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material to the new employees' employment.
*this image is generated using AI for illustrative purposes only.
Vera Therapeutics, Inc., a commercial-stage biotechnology company based in Brisbane, California, announced on July 10, 2026, that its Compensation Committee granted inducement awards to eight new employees. The grants, made on July 6, 2026, were approved under the Vera Therapeutics, Inc. 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), which permits such awards as an inducement material to new employees' employment.
Grant Details
The inducement awards consist of two components: non-qualified stock options and restricted stock units (RSUs). The table below summarizes the key parameters of the grants:
| Parameter: | Details |
|---|---|
| Grant Date: | July 6, 2026 |
| Number of Recipients: | 8 new employees |
| Stock Options (Shares): | 32,100 shares of Class A common stock |
| RSUs (Shares): | 16,050 shares of Class A common stock |
| Exercise Price per Share: | $40.13 |
| Governing Plan: | 2024 Inducement Plan |
| Applicable Rule: | Nasdaq Listing Rule 5635(c)(4) |
Vesting Schedule
The stock options and RSU awards each carry a four-year vesting schedule, with distinct structures for each award type:
Stock Options:
- 25% of the underlying shares vest on the first anniversary of the applicable vesting commencement date
- The remaining balance vests monthly over the subsequent 36 months
- Vesting is subject to the new employee's continued service relationship with Vera Therapeutics through the applicable vesting dates
RSU Awards:
- 25% of the underlying shares vest on each anniversary of August 20
- Vesting is subject to the new employee's continued service relationship with Vera Therapeutics through the applicable vesting dates
All awards are subject to the terms and conditions of the 2024 Inducement Plan and the applicable award agreement covering each grant.
About Vera Therapeutics
Vera Therapeutics is a commercial-stage biotechnology company focused on autoimmune disease, with a particular emphasis on kidney-related conditions. The company's flagship commercial product is TRUTAKNA™ (atacicept-vymj), a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor. Vera Therapeutics is evaluating multiple diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. The company was founded in 2016 and is headquartered in Brisbane, California.
What specific roles or expertise do these eight new hires bring to support the commercialization of TRUTAKNA™?
How will the dilution from these inducement awards impact existing shareholders as the company scales?
Does this hiring signal an acceleration in the commercial rollout or expansion into new indications for TRUTAKNA™?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
